Inhibition of Retroviral LTR Promoters by Calcium Response Modifiers
Posted Jun 02 2010 5:00pm
Description of Invention: The human immunodeficiency virus (HIV) LTR is synergistically activated by the phorbol ester 12-myristic 13-acetate (PMA) and T cell specific mitogenic lectin phytohemagglutinin A (PHA). This reflects the activation of the HIV LTR by endogenous T cell mechanisms in vitro. A class of non-voltage-gated calcium influx inhibitor compounds is disclosed which is newly discovered to inhibit the activation of retroviral LTR promoters, including HIV-LTR, by PHA and PMA. This class of compounds can be used to delay or suppress the transition of HIV infection from a latent to a virulent condition, thereby preventing or ameliorating retroviral diseases such as Acquired Immune Deficiency Syndrome (AIDS). The compounds are also useful in cancer treatment, allowing for coordinated therapeutic approaches to retroviral disease and related cancers such Kaposi's Sarcoma. The compounds can also be used to standardize in vitro assays of commercial importance for clinical and experimental application.
Inventors: Elise C Kohn (NCI) Kevin Gardner (NCI) Lance A Liotta (NCI)
Portfolios: Cancer Cancer - Therapeutics Cancer - Research Materials Infectious Diseases Infectious Diseases - Therapeutics Infectious Diseases - Research Materials In-vitro Data
For Additional Information Please Contact: Sally Hu Ph.D., M.B.A. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 21, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5606 Fax: 301-402-0220